Although whole-exome sequencing (WES) is the gold standard for the diagnosis of neurodevelopmental disorders (NDDs), it remains expensive for some genetic centers. Commercialized panels comprising all OMIM-referenced genes called "medical exome" (ME) constitute an alternative strategy to WES, but its efficiency is poorly known. In this study, we report the experience of 2 clinical genetic centers using ME for diagnosis of NDDs. We recruited 216 consecutive index patients with NDDs in 2 French genetic centers, corresponded to the daily practice of the units and included non-syndromic intellectual disability (NSID, n = 33), syndromic ID (NSID = 122), pediatric neurodegenerative disorders (n = 7) and autism spectrum disorder (ASD, n = 54). We sequenced samples from probands and their parents (when available) with the Illumina TruSight One sequencing kit. We found pathogenic or likely pathogenic variants in 56 index patients, for a global diagnostic yield of 25.9%. The diagnosis yield was Laurent Pasquier and Cyril Mignot contributed equally to this study.
higher in patients with ID as the main diagnosis (32%) than in patients with ASD (3.7%). Our results suggest that the use of ME is a valuable strategy for patients with ID when WES cannot be used as a routine diagnosis tool.
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| INTRODUCTION
Intellectual disability (ID) is the most frequent neurodevelopmental disorder (NDD) affecting about 1% to 3% of the population worldwide. More than 700 genes are known to cause ID 1 and this large genetic heterogeneity is challenging for diagnosis because the phenotype in many patients is either non-syndromic or corresponds to syndromes that are either not recognized or for which the molecular cause is still unknown. To decipher the genetic etiologies of NDD, chromosomal microarray is a first tier diagnosis tool, 2 together with the search for a FMR1 gene 5 0 untranslated region (5 0 UTR) triplet amplification. When these investigations are negative and if no targeted genetic testing is considered, clinical geneticists have to choose between gene panels 3 and whole-exome sequencing (WES). Because of the extreme genetic heterogeneity of NDD and because each genetic cause is very rare, the probability to find molecular causes of NDD tends to increase with the number of analyzed genes, which implies that WES is a more appropriate tool than gene panels. [4] [5] [6] [7] However, the cost of WES is still high and unaffordable in daily practice for many genetic centers that have to choose between locally designed gene panels and commercialized gene panels comprising all known disease-related genes, called "medical exome" (ME). A few articles reported the use of ME for the diagnosis of genetic disorders. 8, 9 We report here the experience of 2 French genetic centers using the TruSight One sequencing panel, which targets genes associated with known phenotypes, for the diagnosis of NDD in 216 patients.
| MATERIAL AND METHODS

| Patients
We studied 216 index patients with a presumed genetic NDD but without molecular etiology recruited consecutively in the daily practice of 2 clinical genetic centers (Groupe Hospitalier Pitié-Salpêtrière and Centre Hospitalier Universitaire of Rennes). Inclusion criteria were: (1) the family asks for the establishment of a definite risk for a first-degree relative of having a child with the disease of the index case, (2) negative previous genetic testing including chromosomal microarray analysis, fragile X testing, as well as normal metabolic screening and/or targeted genetic studies varying from one patient to another.
The overall series included 133 males and 83 females. Ages at disease onset ranged from 1 to 56 years. Consanguinity was reported in 17 families (7.8%). Intriguingly, for patient #53, we identified 2 heterozygous de novo variants in the same gene SMARCA2 responsible for NicolaidesBaraitser syndrome. We were not able to answer about the cis/trans position. Indeed, we confirmed that both variations were not present in parent's DNA within Sanger sequencing method and were not located on the same read, looking at our NGS data.
| Rate of diagnoses and phenotypes
Diagnostic yields according to the phenotypic categories defined above (Table S1) Pathogenic variants identified in KAL1 in patient #57 and PRODH in patient #58 partly explained their SID phenotypes (hypogonadotrophic hypogonadism and ID with schizophrenia, respectively).
| DISCUSSION
Many previous studies have shown that WES is an excellent option for genetic testing in patients with NDD when fragile X syndrome, chromosomal imbalances and other hypotheses with available targeted genetic studies have been ruled out. [4] [5] [6] [7] The huge genetic heterogeneity of NDD and the rarity of each cause imply that the likelihood of finding pathogenic variants increases with the number of the studied genes. ME, i.e. panels including all disease-associated genes, is an alternative strategy when WES is not available or too expensive. In the only article reporting of the use of the TruSight One gene panel in the daily practice, this panel was applied to the diagnosis of all kinds of genetic diseases. 8 Our study on patients with NDD only provides more insight into the use of ME in a context of extreme genetic heterogeneity.
| Mutated genes and associated phenotypes
As in series of patients with NDD studied by WES, 4-7 genetic heterogeneity was the rule in our series since we found pathogenic variants in 48 different genes involved in NDD (excluding KAL1). Eight genes were found mutated twice (ARID1B, STXBP1, SCN2A, SYNGAP1, TCF4, ANKRD11, ADNP and ATP1A3). As expected, 6 of these genes are among the most frequently mutated in the DDD study reporting pathogenic variants found by WES in individuals with developmental disorders. 7 Most gene panels are targeted to the molecular investigation of patients with particular phenotypes. Because of the large clinical and molecular heterogeneity of NDD, the search for its etiology requires testing with panels comprising hundreds of genes or an informative clinical examination allowing the targeting of specific panels. Using ME sequencing, we identified the etiology of NDD in 53 of 56 patients Abbreviations: AD, autosomal dominant; AR, autosomal recessive; cht, compound heterozygous; F, female; hi, hemizygous; hm, homozygous; ht, heterozygous; M, male; ME, medical exome; NDD, neurodevelopmental disorder; XL, X-linked. Likewise, the de novo heterozygous truncating variant identified in PHIP in patient #49 with syndromic ID became the likely cause of his NDD after the publication of 2 other patients. 26 We found a de novo heterozygous truncating variant in RORA in patient #50 with ataxia, epilepsy and severe ID. RORA encodes the retinoic-acid orphan receptor alpha expressed in the brain 27 
| Diagnosis rate
We obtained a global diagnostic yield of 25.9%. The diagnostic yield of WES for all types of genetic diseases, most of which are developmental disorders, is 25% to 32% when index cases only are studied 4, 5 and raises to 30% to 38.5% with trios, 7,29 mainly because variants are discovered in "new" genes. Thus, our results are lower but close to those obtained with WES performed with index cases only. However, the diagnosis rate is obviously limited with ME because new genes involved in NDD are regularly identified. We identified a pathogenic mutation in 4 of 7 patients with NDEG but this number is too small to discuss the efficiency of ME in this clinical context. The 32% of diagnoses in patients with ID vs 3.7% in those with ASD is related to our classification of NDD. Some patients meeting the ADI criteria for ASD were classified in the SID and NSID groups because of early developmental delay suggesting that ASD was a manifestation of their NDD rather than the NDD itself. As examples, this was the case for patient #2 with a variant in ADNP and for patient #32 with a variant in SYNGAP1. Patients with ASD in our study roughly corresponds to the "essential" ASD group defined in a previous article 22 in which trio-based WES revealed a pathogenic variant in 2 of 64 patients (3.1%). This result is close to ours and suggests that careful selection of patients with NDD may help defining subgroups of patients with a higher probability of achieving a molecular diagnosis.
| Proposition of a rational use of ME in a context of economic constraints
Despite the diagnostic efficiency of WES for patients with NDD, some genetic centers cannot use it in their daily practice because of its high cost. The TruSight One gene panel covers 12 Mb of the genome while WES kits cover about 60 Mb. When studying trios with the ME, 36 Mb are sequenced, which is 60% of the coverage for 1 WES. Given that the cost per base is set with a given sequencing kit and that the cost of library preparations is comparable between kits, ME in trios (for 1 patient) represents a 40% saving on sequencing reagents compared with WES in index cases at constant depth.
The diagnostic yield is markedly increased by the sequencing strategy of trios vs index cases with WES. 29 The aim of our study was not to compare trios vs index cases (or duos) with ME. As demonstrated by the previous series of ME, 8 the "index case" strategy may reveal pathogenic variants when specific genes are suspected. Because of the low rate of diagnoses obtained with index cases (or duos) in our first sequencing series of patients without clinical diagnosis, we decided to use trio-based sequencing when possible. Although the cost of sequencing is 3 times higher than with index cases, this strategy greatly facilitates the downstream analyses and variant interpretation by allowing to detect de novo and compound heterozygous variants and reduces the cost of Sanger cosegregation analysis.
We conclude that for centers that do not use WES for routine diagnoses, trio-based ME may be considered as a useful alternative strategy to investigate NDD. The rate of diagnoses can be further improved by selecting patients with the highest likelihood of achieving a molecular diagnosis, that is, those with ID or NDEG.
